Sean Marett was a member of the management board of BioNTech from 2012 to 2024. In his 12 years on the board, he played a significant role in the company’s growth and global expansion through leading fundraising, business development and product commercialization activities which generated over $22 billion in cash for BioNTech to June 2024.
Earlier in his career, he worked in commercial roles in Pfizer and GSK in Europe and in the USA as well as working for European biotech, manufacturing and research service companies. He also served as non-executive director of Bambusa Therapeutics Inc, KWS Biotest Ltd and PHMR Ltd, the latter two of which he helped to exit through trade sales.
Sean currently serves as non-executive director of the biotechnology company Bisirna Therapeutics and the medical device company Therakos Healthcare Limited. He has been honored with a number of awards and recognitions, including the Companion of the Most Distinguished Order of St Michael and St George awarded by Her Majesty Queen Elizabeth II, the then monarch of the United Kingdom. He holds a BSc (Hons) in Biochemistry from Kings College London and an MBA from Manchester Business School in the UK.
